Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?
Zedenius
Jan
J
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004067:Digestive System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D019317:Evidence-Based Medicine; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000532:radiotherapy; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000187:drug effects; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D010456:Peptides, Cyclic; D011868:Radioisotopes; D017481:Receptors, Somatostatin; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide